350 related articles for article (PubMed ID: 37510143)
1. Exploring the Molecular Complexity of Medulloblastoma: Implications for Diagnosis and Treatment.
Rechberger JS; Toll SA; Vanbilloen WJF; Daniels DJ; Khatua S
Diagnostics (Basel); 2023 Jul; 13(14):. PubMed ID: 37510143
[TBL] [Abstract][Full Text] [Related]
2. Childhood Medulloblastoma: Current Therapies, Emerging Molecular Landscape and Newer Therapeutic Insights.
Khatua S; Song A; Citla Sridhar D; Mack SC
Curr Neuropharmacol; 2018; 16(7):1045-1058. PubMed ID: 29189165
[TBL] [Abstract][Full Text] [Related]
3. The Neurodevelopmental and Molecular Landscape of Medulloblastoma Subgroups: Current Targets and the Potential for Combined Therapies.
Slika H; Alimonti P; Raj D; Caraway C; Alomari S; Jackson EM; Tyler B
Cancers (Basel); 2023 Jul; 15(15):. PubMed ID: 37568705
[TBL] [Abstract][Full Text] [Related]
4. MRI features as a helpful tool to predict the molecular subgroups of medulloblastoma: state of the art.
Colafati GS; Voicu IP; Carducci C; Miele E; Carai A; Di Loreto S; Marrazzo A; Cacchione A; Cecinati V; Tornesello A; Mastronuzzi A
Ther Adv Neurol Disord; 2018; 11():1756286418775375. PubMed ID: 29977341
[TBL] [Abstract][Full Text] [Related]
5. Medulloblastoma in China: clinicopathologic analyses of SHH, WNT, and non-SHH/WNT molecular subgroups reveal different therapeutic responses to adjuvant chemotherapy.
Zhang ZY; Xu J; Ren Y; Li KK; Ng HK; Mao Y; Zhong P; Yao Y; Zhou LF
PLoS One; 2014; 9(6):e99490. PubMed ID: 24932704
[TBL] [Abstract][Full Text] [Related]
6. Transcriptome analysis stratifies second-generation non-WNT/non-SHH medulloblastoma subgroups into clinically tractable subtypes.
Korshunov A; Okonechnikov K; Schrimpf D; Tonn S; Mynarek M; Koster J; Sievers P; Milde T; Sahm F; Jones DTW; von Deimling A; Pfister SM; Kool M
Acta Neuropathol; 2023 Jun; 145(6):829-842. PubMed ID: 37093271
[TBL] [Abstract][Full Text] [Related]
7. Molecular Heterogeneity and Cellular Diversity: Implications for Precision Treatment in Medulloblastoma.
Zou H; Poore B; Broniscer A; Pollack IF; Hu B
Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32164294
[TBL] [Abstract][Full Text] [Related]
8. The Current Landscape of Targeted Clinical Trials in Non-WNT/Non-SHH Medulloblastoma.
Ghasemi DR; Fleischhack G; Milde T; Pajtler KW
Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158947
[TBL] [Abstract][Full Text] [Related]
9. Current medulloblastoma subgroup specific clinical trials.
Thompson EM; Ashley D; Landi D
Transl Pediatr; 2020 Apr; 9(2):157-162. PubMed ID: 32477916
[TBL] [Abstract][Full Text] [Related]
10. Molecular Stratification of Medulloblastoma: Clinical Outcomes and Therapeutic Interventions.
Sursal T; Ronecker JS; Dicpinigaitis AJ; Mohan AL; Tobias ME; Gandhi CD; Jhanwar-Uniyal M
Anticancer Res; 2022 May; 42(5):2225-2239. PubMed ID: 35489737
[TBL] [Abstract][Full Text] [Related]
11. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial.
Goschzik T; Schwalbe EC; Hicks D; Smith A; Zur Muehlen A; Figarella-Branger D; Doz F; Rutkowski S; Lannering B; Pietsch T; Clifford SC
Lancet Oncol; 2018 Dec; 19(12):1602-1616. PubMed ID: 30392813
[TBL] [Abstract][Full Text] [Related]
12. Molecular markers and potential therapeutic targets in non-WNT/non-SHH (group 3 and group 4) medulloblastomas.
Menyhárt O; Giangaspero F; Győrffy B
J Hematol Oncol; 2019 Mar; 12(1):29. PubMed ID: 30876441
[TBL] [Abstract][Full Text] [Related]
13. Signaling pathway and molecular subgroups of medulloblastoma.
Li KK; Lau KM; Ng HK
Int J Clin Exp Pathol; 2013; 6(7):1211-22. PubMed ID: 23826403
[TBL] [Abstract][Full Text] [Related]
14. Decoding Somatic Driver Gene Mutations and Affected Signaling Pathways in Human Medulloblastoma Subgroups.
Robbins CJ; Bou-Dargham MJ; Sanchez K; Rosen MC; Sang QA
J Cancer; 2018; 9(24):4596-4610. PubMed ID: 30588243
[TBL] [Abstract][Full Text] [Related]
15. Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups.
Ellison DW; Dalton J; Kocak M; Nicholson SL; Fraga C; Neale G; Kenney AM; Brat DJ; Perry A; Yong WH; Taylor RE; Bailey S; Clifford SC; Gilbertson RJ
Acta Neuropathol; 2011 Mar; 121(3):381-96. PubMed ID: 21267586
[TBL] [Abstract][Full Text] [Related]
16. Medulloblastoma: optimizing care with a multidisciplinary approach.
Thomas A; Noël G
J Multidiscip Healthc; 2019; 12():335-347. PubMed ID: 31118657
[TBL] [Abstract][Full Text] [Related]
17. Medulloblastoma: "Onset of the molecular era".
Dhanyamraju PK; Patel TN; Dovat S
Mol Biol Rep; 2020 Dec; 47(12):9931-9937. PubMed ID: 33159234
[TBL] [Abstract][Full Text] [Related]
18. Signaling pathway and molecular subgroups of medulloblastoma. Int J Clin Exp Pathol. 2013; 6(7): 1211-22.
Li KK; Lau KM; Ng HK
Int J Clin Exp Pathol; 2015; 8(9):11945. PubMed ID: 26617952
[TBL] [Abstract][Full Text] [Related]
19. Targeting the PI3K/AKT/mTOR signaling pathway in medulloblastoma.
Dimitrova V; Arcaro A
Curr Mol Med; 2015; 15(1):82-93. PubMed ID: 25601471
[TBL] [Abstract][Full Text] [Related]
20. Molecular stratifications, biomarker candidates and new therapeutic options in current medulloblastoma treatment approaches.
Menyhárt O; Győrffy B
Cancer Metastasis Rev; 2020 Mar; 39(1):211-233. PubMed ID: 31970590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
